검색어 : 통합검색[Sutherland Joan]
총 94건 중 94건 출력
, 8/10 페이지
-
71
- In the shade of “beautiful style”: talking about the chamber vocal music pieces by G. Donizetti
- Anfi lovaS. G.; ; (Aspects of Historical Musicology, v.15, 2019, pp.99-118)
-
72
- Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma
- Orlowski, Robert Z.; Nagler, Arnon; Sonneveld, Pieter; Bladé , Joan; Hajek, Roman; Spencer, Andrew; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J.; Suvorov, Alexander; Xiu, Liang; Parekh, Trilok V.; Miguel, Jesú s San; The University of Texas MD Anderson Cancer Center, Houston, TX; EBMT Acute Leukemia Working Party and Registry, Hematology Division, BMT and Cord Blood Bank, Tel-Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Ramat- Gan, Israel; Erasmus MC Cancer Institute, Rotterdam, Netherlands; M.D Hospital Clinic, Barcelona, Spain; Masaryk University, Brno, Czech Republic; Alfred Hospital, Melbourne, Australia; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; Medical University of Lublin, Lublin, Poland; Royal Adelaide Hospital, SA Pathology, SA, Australia; Charles University, Prague, Czech Republic; University of British Columbia, Vancouver, Canada; First Republican Clinical Hospital of Ministry of Healthcare of the Udmurt Republic, Izhevsk, Russia; Janssen Research & Development, Raritan,; Janssen Research & Development, Raritan,; Hospital Universitario Salamanca, Salamanca, Spain; (Blood, v.124, 2014, pp.3448-3448)
-
73
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
-
Orlowski, Robert Z.;
Nagler, Arnon;
Sonneveld, Pieter;
Bladé
, Joan;
Hajek, Roman;
Spencer, Andrew;
Robak, Tadeusz;
Dmoszynska, Anna;
Horvath, Noemi;
Spicka, Ivan;
Sutherland, Heather J.;
Suvorov, Alexander N.;
Xiu, Liang;
Cakana, Andrew;
Parekh, Trilok;
San‐
Miguel, Jesú
s F.;
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas;
Division of Hematology, Chaim Sheba Medical Center, Tel‐
Hashomer, Israel;
Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands;
Department of Clinical Hematology, August Pi I Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain;
Department of Hemato‐
Oncology, University Hospital and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
Malignant Hematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia;
Department of Hematology, Medical University of Łó
dź
, Łó
dź
, Poland
pl
-
74
- The PISQ-IR: considerations in scale scoring and development
- Rockwood, Todd H.; Constantine, Melissa L.; Adegoke, Olusola; Rogers, Rebecca G.; McDermott, Elektra; Davila, G. Willy; Domoney, Claudine; Jha, Swati; Kammerer-Doak, Dorothy; Lukacz, Emily S.; Parekh, Mitesh; Pauls, Rachel; Pitkin, Joan; Reid, Fiona; Ridgeway, Beri; Thakar, Ranee; Sand, Peter K.; Sutherland, Suzette E.; Espuna-Pons, Montserrat; ; (International urogynecology journal, v.24, 2013, pp.1105-1122)
-
75
- Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
- Orlowski, Robert Z.; Nagler, Arnon; Sonneveld, Pieter; Bladé , Joan; Hajek, Roman; Spencer, Andrew; San Miguel, Jesú s; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J.; Suvorov, Alexander N.; Zhuang, Sen H.; Parekh, Trilok; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne; Harousseau, Jean-Luc; From the University of North Carolina at Chapel Hill, Chapel Hill, NC; Chaim Sheba Medical Center, Tel Hashomer, Israel; Erasmus MC, Rotterdam, the Netherlands; Hospital Clinic I Provincial, Barcelona, Spain; Interní Hematoonkologická klinika Fakultní Brno, Brno; General Faculty Hospital, Prague, Czech Republic; Alfred Hospital, Melbourne; Institute of Medicine and Veterinary Science, Adelaide, Australia; Hospital Universitario de Salamanca, Centro de Investigació n del Cá ncer- IBMCC (CSIC-USAL), Spain; ...; From the University of North Carolina at Chapel Hill, Chapel Hill, NC; Chaim Sheba Medical Center, Tel Hashomer, Israel; Erasmus MC, Rotterdam, the Netherlands; Hospital Clinic I Provincial, Barcelona, Spain; Interní Hematoonkologická klinika Fakultní Brno, Brno; General Faculty Hospital, Prague, Czech Republic; Alfred Hospital, Melbourne; Institute of Medicine and Veterinary Science, Adelaide, Australia; Hospital Universitario; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.25, 2007, pp.3892-3901)
-
76
- Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.
- Orlowski, Robert Z.; Gercheva, Liana; Williams, Cathy; Sutherland, Heather J; Robak, Tadeusz; Masszi, Tamá s; Goranova-Marinova, Vesselina; Dimopoulos, Meletios A.; Cavenagh, James D.; Spicka, Ivan; Maiolino, Angelo; Suvorov, Alexander; Blade, Joan; Samoilova, Olga S; Van De Velde, Helgi; Bandekar, Rajesh; Kranenburg, Britte; Xie, Hong; Rossi, Jean-Francois; University of Texas M. D. Anderson Cancer Center, Houston, TX; University Multiprofile Hospital for Active Treatment, Varna, Bulgaria; Nottingham University Hospitals, Nottingham, United Kingdom; Vancouver General Hospital, Vancouver, BC, Canada; Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; St. Istvá n and St. Lá szló Hospital, Budapest, Hungary; University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria; Alexandra Hospital, Athens, Greece; St Bartholomew's Hospital, London, United Kingdom; Charles University in Prague, Prague, Czech Republic; Hospital Universitá rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 1st Republican Clinical Hospital of Udmurtia, Izhevsk, Russia; Hospital Clinic de Barcelona, Barcelona, Spain; Nizhnii Novgorod Regional Clinical Hospital, Nizhnii Novgorod, Russia; Janssen Research & Development, Beerse, Belgium; Janssen Research & Deve; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.30, 2012, pp.8018-8018)
-
77
- Interventions that have potential to help older adults living with social frailty: a systematic scoping review
- Kastner, Monika; Herrington, Isabella; Makarski, Julie; Amog, Krystle; Bain, Tejia; Evangelista, Vianca; Hayden, Leigh; Gruber, Alexa; Sutherland, Justin; Sirkin, Amy; Perrier, Laure; Graham, Ian D.; Greiver, Michelle; Honsberger, Joan; Hynes, Mary; Macfarlane, Charlie; Prasaud, Leela; Sklar, Barbara; Twohig, Margo; Liu, Barbara; Munce, Sarah; Marr, Sharon; O’Neill, Braden; Papaioannou, Alexandra; Seaton, Bianca; Straus, Sharon E.; Dainty, Katie; Holroyd-Leduc, Jayna; ; (BMC geriatrics, v.24, 2024, pp.521)
-
78
- Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
- Lonial, Sagar; Weiss, Brendan M.; Usmani, Saad Zafar; Singhal, Seema; Chari, Ajai; Bahlis, Nizar J.; Belch, Andrew; Krishnan, Amrita Y.; Vescio, Robert A.; Mateos, Marí a-Victoria; Mazumder, Amitabha; Orlowski, Robert Z.; Sutherland, Heather J; Blade, Joan; Scott, Emma Catherine; Feng, Huaibao; Khan, Imran; Uhlar, Clarissa M.; Ahmadi, Tahamtan; Voorhees, Peter Michael; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Division of Hematology & Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC; Robert H. Lurie Comprehensive Cancer Center, Division of Hem./Onc., Northwestern University Feinberg School of Medicine, Chicago, IL; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada; Cross Cancer Institute, Department of Medical Oncology, Edmonton, AB, Canada; Department Hematology and Hematopoietic Stem Cell Transplant, City of Hope, Duarte, CA; Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA; University Hospital of Salamanca/IBSAL, Salamanca, Spain; NYU Perlmutter Cancer Center, New York, NY; Department of Lymphoma/Myeloma, Th; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.LBA8512-LBA8512)
-
79
- <i>Burkholderia phymatum</i> is a highly effective nitrogen‐fixing symbiont of <i>Mimosa</i> spp. and fixes nitrogen <i>ex planta</i>
- Elliott, Geoffrey N.; Chen, Wen‐ Ming; Chou, Jui‐ Hsing; Wang, Hui‐ Chun; Sheu, Shih‐ Yi; Perin, Liamara; Reis, Veronica M.; Moulin, Lionel; Simon, Marcelo F.; Bontemps, Cyril; Sutherland, Joan M.; Bessi, Rosana; De Faria, Sergio M.; Trinick, Michael J.; Prescott, Alan R.; Sprent, Janet I.; James, Euan K.; School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK; ; Laboratory of Microbiology, Department of Seafood Science, National Kaohsiung Marine University, Kaohsiung City 811, Taiwan; ; Laboratory of Microbiology, Department of Seafood Science, National Kaohsiung Marine University, Kaohsiung City 811, Taiwan; ; Laboratory of Microbiology, Department of Seafood Science, National Kaohsiung Marine University, Kaohsiung City 811, Taiwan; ; Department of Marine Biotechnology, National Kaohsiung Marine University, Kaohsiung, Taiwan; ; EMBRAPA‐ Agrobiologia, km 47, Seropé dica, 23851‐ 970, RJ, Brazil; ; EMBRAPA‐ Agrobiologia, km 47, Seropé dica, 23851‐ 970, RJ, Brazil; ; Laboratoire des Symbioses Tropicales & Mé diterrané ennes IRD/CIRAD/INRA/AGROM/UMII, Campus de Baillarguet, 34398 Montpellier cedex 5, France; ; Embrapa Sede, PqEB s/n, Brasilia, 70770‐ 901, DF, Brazil; ; Department of Biology 3, University of York, PO Box 373, Y; (The New phytologist, v.173, 2007, pp.168-180)
-
80
- Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
- Lonial, Sagar; Weiss, Brendan M.; Usmani, Saad Zafar; Singhal, Seema; Chari, Ajai; Bahlis, Nizar J.; Belch, Andrew; Krishnan, Amrita Y.; Vescio, Robert A.; Mateos, Marí a-Victoria; Mazumder, Amitabha; Orlowski, Robert Z.; Sutherland, Heather J; Blade, Joan; Scott, Emma Catherine; Feng, Huaibao; Khan, Imran; Uhlar, Clarissa M.; Ahmadi, Tahamtan; Voorhees, Peter Michael; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Division of Hematology & Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC; Robert H. Lurie Comprehensive Cancer Center, Division of Hem./Onc., Northwestern University Feinberg School of Medicine, Chicago, IL; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada; Cross Cancer Institute, Department of Medical Oncology, Edmonton, AB, Canada; Department Hematology and Hematopoietic Stem Cell Transplant, City of Hope, Duarte, CA; Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA; University Hospital of Salamanca/IBSAL, Salamanca, Spain; NYU Perlmutter Cancer Center, New York, NY; Department of Lymphoma/Myeloma, Th; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.LBA8512-LBA8512)
QUICK MENU
